BALNEOTHERAPY FOR BREAST CANCER PATIENTS UNDERGOING ENDOCRINE THERAPY

Endocrine therapy is the mainstay of adjuvant therapy in premenopausal women with hormone receptive-positive (HR+) breast cancer as it has been demonstrated that it reduces long-term recurrences and increases survivial. However, this therapy, which suppresses estrogen production and estrogen-induced effects, is associated with the development of joint pain which can significantly reduce quality of life and lead to treatment discontinuation. The main question the study aims o answer is: Can balneotherapy (BT) alleviate muscle-skeletal pain (primary objective) derived from endocrine therapy and improve quality of life (secondary objective) in young women with HR+ breast cancer?

NCT Number	NCT06806072
Lead Sponsor	Parc de Salut Mar Collaborators: Caldes de Montbui's City Council, European Regional Development Fund, Biomedical Research Networking Center on Frailty and Healthy Aging (CIBERFES)
Conditions	Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Enrollment	96 participants
Start Date	2025-02-10
Primary Completion	2026-08-30 (estimated)
Study Completion	2027-05-31 (estimated)
Updated on ClinicalTrials.gov	2025-02-03